查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
全球抗體藥物複合體(ADC)成長機會，預測至2028年
市場調查報告書
商品編碼
1322942

全球抗體藥物複合體(ADC)成長機會，預測至2028年

Global Antibody Drug Conjugate (ADC) Growth Opportunities, Forecast to 2028
出版日期: | 出版商: Frost & Sullivan | 英文 55 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

與創新平台開發商的合作推動成長潛力

本研究服務提供了全球 ADC 市場的概況，並提供了從2023年到2028年的六年收入預測。 ADC 由多個組件結構，例如抗體、共軛化學、連接子和有效負載。市場競爭非常激烈，許多公司致力於每個結構要素，而其他公司則僅開發 ADC。超越標準抗體的靶向遞送載體的開發提高這些藥物的效力並開闢新的癌症治療可能性。新技術目的是解決現有 ADC 技術的缺點，包括穩定性低、耐受性差、療效低、治療指數窄以及 ADC 製造方面的挑戰。

根據 Frost & Sullivan 的分析，依賴委外研發機構(CDMO)/契約委外研發機構(CRO) 進行早期藥物開發的中小企業創造新型抗體治療技術。許多抗體開發商減少內部研發工作，並增加抗體治療產品線的許可和收購，以加強其管道。所有主要 CDMO 都在進行新投資以支持下一代 ADC，使該細分市場更具競爭力。生物製藥公司轉向 ADC，以從選擇性腫瘤抗原的靶點特異性中獲益。 ADC 在過去兩年中已獲得七項批准，反映出開發人員使用穩健的方法來提高有效負載效力的成功率。

本報告中包含的其他資訊包括：

  • 市場趨勢
  • 主要破壞者
  • 推動血液腫瘤和實體瘤成長的 ADC 市場投入和產品線
  • 相關人員可以利用的領域成長機會

目錄

戰略問題

  • 為什麼成長如此困難？
  • The Strategic Imperative 8（TM）
  • ADC 行業三大戰略問題的影響
  • 支撐成長管道引擎 (TM) 的成長機會

成長環境

  • 分析範圍
  • ADC 市場亮點
  • 成長機會：ADC 市場
  • 成長促進因素
  • 生長阻礙因素
  • 藥物偶聯物的歷史、進展和研究階段
  • ADC市場趨勢
  • ADC技術的演變
  • ADC 的精準腫瘤學方法
  • 生物標記在癌症領域的應用
  • 生命週期管理策略
  • ADC交易與投資預測
  • 關注的 ADC 合作夥伴和聯盟 (2022)
  • 關注的 ADC 合作夥伴和聯盟（2022年和2023年）
  • 批准的 ADC 血液系統惡性腫瘤
  • 批准的 ADC 實體瘤
  • 關注的後期 ADC

收入預測與分析

  • 預測假設
  • 成長指數
  • 收入預測
  • 盈利預測分析：實體瘤（已上市）
  • 盈利預測分析：實體瘤（研發產品線）
  • 盈利預測分析：血液癌症（已上市）
  • 盈利預測分析：血液癌症（後期研發產品線）

採取行動的公司 擾亂 ADC 市場的公司

  • Tubulis 廣泛的技術平台
  • LCB：共軛技術平台
  • Synaffix (Lonza)：端到端 ADC 服務
  • WuXi Biologics：ADC CRDMO
  • Mersana Therapeutics 後期 ADC 管道和平台
  • Ixuda ADC 開發的工具箱方法

成長機會宇宙

  • 成長機會1：精準化療的ADC聯合療法
  • 成長機會2：CDMO與早期平台和ADC開發商之間的戰略合作夥伴關係
  • 成長機會3：新型連接子和共軛化學
  • 圖表列表
  • 免責聲明
簡介目錄
Product Code: PED8-52

Collaborations with Innovative Platform Developers will Drive Growth Potential

This research service overviews the global ADC market and provides a 6-year revenue forecast from 2023 to 2028. An ADC comprises multiple components such as the antibody, conjugation chemistry, linker, and payload. Many companies are working on each component while others only develop ADCs, which makes the market highly competitive. The development of targeted delivery vehicles over standard antibodies is improving the performance of these drugs and expanding their potential for treating new cancers. New technologies are trying to address drawbacks of existing ADC technology, such as poor stability, leading to poor tolerability, efficacy, and a narrow therapeutic index and challenging ADC manufacturing.

Frost & Sullivan's analysis shows that small and mid-sized enterprises that rely on contract development and manufacturing organizations (CDMOs)/contract research organizations (CROs) for initial drug development create novel antibody therapeutic technologies. Many antibody developers have been decreasing in-house R&D efforts and increasing in-licensing or acquiring therapeutic antibody product lines to strengthen their pipelines. All major CDMOs are stepping up with new investments to support the next generation of ADC, making the segment more competitive. Biopharmaceutical companies are focusing on ADCs to reap the benefits of target specificity for selective tumor antigens. Developers are using robust approaches to improve payloads' potency as ADCs reflect the success rate in the last two years with seven approvals.

Other information included in the report consists of the following:

  • Market trends
  • Leading disruptors
  • Marketed and pipeline ADC that will drive growth in hematological and solid tumors
  • Growth opportunities emerging from this space that stakeholders can leverage

Table of Contents

Strategic Imperatives

  • Why Is It Increasingly Difficult to Grow?
  • The Strategic Imperative 8™
  • The Impact of the Top 3 Strategic Imperatives on the ADC Industry
  • Growth Opportunities Fuel the Growth Pipeline Engine™

Growth Environment

  • Scope of Analysis
  • ADC Market Highlights
  • Growth Opportunities: The ADC Market
  • Growth Drivers
  • Growth Restraints
  • Drug Conjugates' History, Progress, and Research Stages
  • ADC Market Trends
  • ADC Technology Evolution
  • Precision Oncology Approaches for ADCs
  • Biomarker Application Across the Cancer Continuum
  • Life Cycle Management Strategies
  • ADC Deals and Investment Outlook
  • Notable ADC Partnerships and Collaborations, 2022
  • Notable ADC Partnerships and Collaborations, 2022 and 2023
  • Approved ADCs: Hematological Cancer
  • Approved ADCs: Solid Tumors
  • Late-stage ADCs to Watch

Revenue Forecast and Analysis

  • Forecast Assumptions
  • Growth Metrics
  • Revenue Forecast
  • Revenue Forecast Analysis: Solid Tumors (Launched)
  • Revenue Forecast Analysis: Solid Tumors (Pipeline)
  • Revenue Forecast Analysis: Hematological Cancer (Launched)
  • Revenue Forecast Analysis: Hematological Cancer (Late-stage Pipeline)

Companies to Action: ADC Market Disruptors

  • Tubulis: Broad Spectrum of Technology Platforms
  • LCB: Conjugation Technology Platforms
  • Synaffix (Lonza): End-to-end ADC Services
  • WuXi Biologics: ADC CRDMO
  • Mersana Therapeutics: Late-stage ADC Pipeline and Platform
  • Iksuda: A Toolbox Approach for ADC Development

Growth Opportunity Universe

  • Growth Opportunity 1: ADC Combination Therapies for Precision Chemotherapeutics
  • Growth Opportunity 2: Strategic Partnerships between CDMOs and Early-stage Platform and ADC Developers
  • Growth Opportunity 3: Novel Linkers and Conjugation Chemistries
  • List of Exhibits
  • Legal Disclaimer